2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17587R
    4-Methylbenzylidene camphor (Standard) 36861-47-9 99.60%
    4-Methylbenzylidene camphor (Standard) is the analytical standard of 4-Methylbenzylidene camphor. This product is intended for research and analytical applications. 4-Methylbenzylidene camphor (4-MBC) is an endocrine disrupter that produces estrogen-like effects. 4-Methylbenzylidene camphor decreases the proliferation of human trophoblast cells and induces apoptosis. 4-Methylbenzylidene camphor activates PI3K/AKT and ERK1/2 signaling pathways and elevates intracellular ROS production. 4-Methylbenzylidene camphor is a ultraviolet (UV) filter and may hamper normal placental formation during early pregnancy.
    4-Methylbenzylidene camphor (Standard)
  • HY-176007
    Fluprostenol methyl amide 98%
    Fluprostenol is a prostaglandin structural analog, and its isopropyl ester derivative (Travoprost, HY-B0584) has demonstrated notable physiological modulatory properties in related studies.
    Fluprostenol methyl amide
  • HY-176104
    (±)9,10-DiHODE(γ)
    (±)9,10-DiHODE(γ), a oxylipin, is a dihydroxyoctadecadienoic acid.
    (±)9,10-DiHODE(γ)
  • HY-176105
    (±)6,7-DiHODE(γ)
    (±)6,7-DiHODE(γ), a oxylipin, is a dihydroxyoctadecadienoic acid.
    (±)6,7-DiHODE(γ)
  • HY-17613S
    Evocalcet-d4 98%
    Evocalcet-d4 (KHK7580-d4) is deuterium labeled Evocalcet. Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism.
    Evocalcet-d4
  • HY-176156
    (±)6(7)-EpODE(γ)
    (±)6(7)-EpODE(γ) ((±)6(7)-Epoxy-γ-octadecadienoic acid) is an epoxy-fatty acid.
    (±)6(7)-EpODE(γ)
  • HY-176157
    12S(13R)-EpODE(γ)
    12S(13R)-EpODE(γ) (12S(13R)-Epoxy-γ-octadecadienoic acid) is an epoxy-fatty acid.
    12S(13R)-EpODE(γ)
  • HY-176158
    (±)9(10)-EpODE(γ)
    (±)9(10)-EpODE(γ) ((±)9(10)-Epoxy-γ-octadecadienoic acid) is an epoxygenated oxylipin.
    (±)9(10)-EpODE(γ)
  • HY-176164
    ALR2-IN-6 98%
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy.
    ALR2-IN-6
  • HY-17623R
    Tegoprazan (Standard) 942195-55-3 98%
    Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro.
    Tegoprazan (Standard)
  • HY-176437
    Tyrosinase-IN-42 1914971-97-3 98%
    Tyrosinase-IN-42 (Compound 13t) is a tyrosinase inhibitor (IC50: 1.363 µM). Tyrosinase-IN-42 exhibits anti-browning effects on fresh-cut apples. Tyrosinase-IN-42 has antioxidant activity by scavenging DPPH and ABTS free radicals (IC50: 57.90 and 45.64 µM, respectively).
    Tyrosinase-IN-42
  • HY-176560
    Raloxifene alkene 184091-74-5 98%
    Raloxifene alkene (Compound 101) is a serum cholesterol clearance agent. Raloxifene alkene has significant anti-proliferation activity against breast adenocarcinoma cells. Raloxifene alkene effectively reduces serum cholesterol level without significant uterine weight and increase of number oieosinoohils in the stromallaver of ovarleclomized rat models. Raloxifene alkene can be used for post-menopausasyndrome, particularly osteoporosis, estrogen-dependent breast and uterine carcinoma research.
    Raloxifene alkene
  • HY-176894
    Hemiacetylcarnitinium chloride 141661-39-4 98%
    Hemiacetylcarnitinium chloride is a inhibitor of fatty acid metabolism, specifically targeting carnitine palmitoyltransferase I (CPT I). Hemiacetylcarnitinium chloride disrupts the conversion of fatty acyl-CoA to fatty acyl carnitine, thereby blocking the subsequent oxidation of long-chain fatty acids and reducing the production of ATP required for energy-dependent cellular processes. Hemiacetylcarnitinium chloride can be used for the study of fatty acid metabolism.
    Hemiacetylcarnitinium chloride
  • HY-176946
    PTH1R agonist 4 3106619-54-6 98%
    PTH1R agonist 4 (Example 63) is a parathyroid hormone 1 receptor (PTH1R) agonist with a pEC50 value greater than 7. PTH1R agonist 4 can be used for the study of bone diseases, such as osteoporosis.
    PTH1R agonist 4
  • HY-176999
    EOTMBA 98%
    EOTMBA is a peptide labeling reagent and can be used for quantitative analysis of dipeptides and tripeptides.
    EOTMBA
  • HY-177440
    T26A 958860-12-3 98%
    T26A is a highly selective prostaglandin transporter (PGT) inhibitor.T26A does not interact with the PGT homolog OATPc, blocks PGT-mediated PGE2 influx, and blocks PGE2 metabolism.T26A retains PGE2 in the extracellular compartment and reduces intracellular PGE2 metabolites.T26A elevates circulating endogenous PGE2 levels, reduces circulating endogenous PGE2 metabolite levels, and slows metabolism of exogenously injected PGE2 in Rattus norvegicus via intravenous injection.T26A does not affect PGE2 synthesis.T26A can be used for the research of PGT function in adult animals.
    T26A
  • HY-177537
    5-Hme-CTP 39749-90-1
    5-Hme-CTP is a monomeric raw material that can be used for nucleic acid synthesis.
    5-Hme-CTP
  • HY-177607
    25-Flurocholesterol 64164-45-0 98%
    25-Flurocholesterol is an oxysterol. 25-Fluorocholesterol increases pigmentation.
    25-Flurocholesterol
  • HY-177702
    Docosapentaenoylcarnitine (C22:5n3) 945955-73-7
    Docosapentaenoylcarnitine (C22:5n3) is an endogenous metabolite of T3D-959.
    Docosapentaenoylcarnitine (C22:5n3)
  • HY-177738
    6'Nicotinate Ac4ManNAz 2102591-12-6
    6'Nicotinate Ac4ManNAz (Compound 2) is a brain-penetrant carbohydrate-neuroactive heteromer conjugating Ac4ManNAz (HY-W728531) and Nicotinic acid (HY-B0143). 6'Nicotinate Ac4ManNAz can be used for the development of glycosylation-regulating agents or diagnostic probes that cross the BBB.
    6'Nicotinate Ac4ManNAz
Cat. No. Product Name / Synonyms Application Reactivity